BPaL Patent Rejection Explained
2.3 Social Justice, Indian Express, 2026-11-06
The Indian Patent Office rejected TB Alliance's patent application for the BPaL combination (bedaquiline, pretomanid, linezolid) following two pre-grant oppositions filed in 2020. India has nearly a quarter of global TB cases, with incidence of 187 per 100,000 in 2024. BPaLM recorded 89 per cent treatment success versus 52-75 per cent for standard regimens. A six-month BPaLM course costs $284, down from $588 in 2022. Over 15,000 patients have started BPaLM under NTEP. Patent approval and CDSCO drug approval are separate processes.